Tamara N. Pereira

Tamara N. Pereira

Auto-generated profile, based on publicly available information

Tamara N. Pereira

Hepatic Fibrosis Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1999 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
APArungundrum S Prakash
Arungundrum S Prakash
TPTamara N Pereira
Tamara N Pereira
PRPaul E.B Reilly
Paul E.B Reilly
ASAlan A Seawright
Alan A Seawright

30 September 2010 in Hepatology
Verified
Journal Article
Open access
PDF file
PLPeter J. Lewindon
Peter J. Lewindon
RSRoss W. Shepherd
Ross W. Shepherd
MWMeagan J. Walsh
Meagan J. Walsh
Ristan GreerRistan Greer
Ristan Greer
RWRichard Williamson
Richard Williamson
GRGrant A. Ramm
Grant A. Ramm
Cystic fibrosis liver disease (CFLD), which results from progressive hepatobiliary fibrosis, is an important cause of morbidity and mortality, but it is difficult to identify before portal hypertension (PHT) ensues. Clinical signs, serum alanine aminotransferase (ALT) levels, and ultrasound (US) are widely applied, but their value in predicting the presence of cirrhosis, the development of PHT, or adverse outcomes is undetermined. The potential gold standard, liver biopsy, is not standard practice and, notwithstanding sampling error considerations, has not been systematically evaluated. Forty patients with cystic fibrosis (median age = 10.6 years) with abnormal clinical, biochemical, and US findings were subjected to dual-pass percutaneous liver biopsy. Clinical outcomes were recorded over 12 years of follow-up (median = 9.5 years for survivors). Logistic regression and receiver operating characteristic analyses were applied to predict hepatic fibrosis (which was assessed by fibrosis staging and quantitative immunohistochemistry) and the occurrence of PHT. PHT occurred in 17 of 40 patients (42%), including 6 of 7 (17%) who died during follow-up. Clinical examination, serum ALT levels, and US findings failed to predict either the presence of liver fibrosis or the development of PHT. Fibrosis staging on liver biopsy, where the accuracy was improved by dual passes ( P = 0.002, nonconcordance = 38%), predicted the development of PHT ( P < 0.001), which occurred more frequently and at a younger age in those with severe fibrosis. Conclusion: Clinical modalities currently employed to evaluate suspected CFLD help to identify a cohort of children at risk for liver disease and adverse outcomes but do not predict an individual's risk of liver fibrosis or PHT development. Liver fibrosis on biopsy predicts the development of clinically significant liver disease. Dual passes help to address sampling concerns. Liver biopsy has a relevant role in the management of patients with suspected CFLD and deserves more widespread application. (Hepatology 2011)

28 January 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
GRGrant A. Ramm
Grant A. Ramm
RSRoss W. Shepherd
Ross W. Shepherd
AHAnita C. Hoskins
Anita C. Hoskins
SGSonia A. Greco
Sonia A. Greco
ANAgnieszka D. Ney
Agnieszka D. Ney
PLPeter J. Lewindon
Peter J. Lewindon
Cholestatic liver diseases, such as cystic fibrosis (CF) liver disease and biliary atresia, predominate as causes of childhood cirrhosis. Despite diverse etiologies, the stereotypic final pathway involves fibrogenesis where hepatic stellate cells (HSCs) are recruited, producing excess collagen which initiates biliary fibrosis. A possible molecular determinant of this recruitment, monocyte chemotaxis protein-1 (MCP-1), an HSC-responsive chemokine, was investigated in CF liver disease and biliary atresia. The bile-duct-ligated rat and in vitro coculture models of cholestatic liver injury were used to further explore the role of MCP-1 in HSC recruitment and proposed mechanism of induction via bile acids. In both CF liver disease and biliary atresia, elevated hepatic MCP-1 expression predominated in scar margin hepatocytes, closely associated with activated HSCs, and was also expressed in cholangiocytes. Serum MCP-1 was elevated during early fibrogenesis. Similar observations were made in bile-duct-ligated rat liver and serum. Hepatocytes isolated from cholestatic rats secreted increased MCP-1 which avidly recruited HSCs in coculture. This HSC chemotaxis was markedly inhibited in interventional studies using anti-MCP-1 neutralizing antibody. In CF liver disease, biliary MCP-1 was increased, positively correlating with levels of the hydrophobic bile acid, taurocholate. In cholestatic rats, increased MCP-1 positively correlated with taurocholate in serum and liver, and negatively correlated in bile. In normal human and rat hepatocytes, taurocholate induced MCP-1 expression. Conclusion: These observations support the hypothesis that up-regulation of hepatocyte-derived MCP-1, induced by bile acids, results in HSC recruitment in diverse causes of cholestatic liver injury, and is a key early event in liver fibrogenesis in these conditions. Therapies aimed at neutralizing MCP-1 or bile acids may help reduce fibro-obliterative liver injury in childhood cholestatic diseases. (Hepatology 2008.)

1 September 1996 in Natural Toxins
Verified
Journal Article
Closed access
PDF file
APArungundrum S. Prakash
Arungundrum S. Prakash
TPTamara N. Pereira
Tamara N. Pereira
BSBarry L. Smith
Barry L. Smith
GSGlen Shaw
Glen Shaw
ASAlan A. Seawright
Alan A. Seawright

1 June 2004 in Hepatology
Verified
Journal Article
Closed access
PDF file
JSJeffery L. Smith
Jeffery L. Smith
PLPeter J. Lewindon
Peter J. Lewindon
AHAnita C. Hoskins
Anita C. Hoskins
TPTamara N. Pereira
Tamara N. Pereira
KSKenneth D. R. Setchell
Kenneth D. R. Setchell
GRGrant A. Ramm
Grant A. Ramm

1 October 2004 in Journal of Hepatology
Verified
Journal Article
Closed access
TPTamara N. Pereira
Tamara N. Pereira
PLPeter J. Lewindon
Peter J. Lewindon
JSJeffery L. Smith
Jeffery L. Smith
TMTherese L. Murphy
Therese L. Murphy
DLDouglas J. Lincoln
Douglas J. Lincoln
GRGrant A. Ramm
Grant A. Ramm